ChemGenex study shows Ceflatonin successful in treatment of chronic myeloid leukemia

By Lisa Kerner

Charlotte, N.C., June 19 - ChemGenex Pharmaceuticals Ltd. said 73.3% of the 15 patients in its study of Ceflatonin (homoharringtonine or HHT) as a treatment for chronic myeloid leukemia (CML) achieved a complete hematologic response after a median of two courses of HHT given in single or combination therapy.

All the patients in the study were resistant to Gleevec or other tyrosine kinase inhibitors.

The data was presented at the European Hematology Association meeting in Amsterdam.

"These results add to the growing body of clinical data that support the potential of HHT as a therapy for CML, especially in the increasing population of patients who have developed bcr-abl mutations associated with resistance to tyrosine kinase inhibitor therapies," chief executive officer Greg Collier said in a company news release.

The company also began a multi-national phase 2/ 3 study evaluating the use of Ceflatonin in patients with chronic, accelerated and blast-phase CML who have the T315I bcr-abl point mutation.

Based in Melbourne, Australia, ChemGenex develops therapeutics in the areas of oncology, diabetes, obesity and depression.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.